|
1
|
Akahani S, Nangia-Makker P, Inohara H, Kim
HR and Raz A: Galectin-3: A novel antiapoptotic molecule with a
functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res.
57:5272–5276. 1997.PubMed/NCBI
|
|
2
|
Danguy A, Camby I and Kiss R: Galectins
and cancer. Biochim Biophys Acta. 1572:285–293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Davidson PJ, Davis MJ, Patterson RJ,
Ripoche MA, Poirier F and Wang JL: Shuttling of galectin-3 between
the nucleus and cytoplasm. Glycobiology. 12:329–337. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin HM, Pestell RG, Raz A and Kim HR:
Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a
cAMP-responsive element in human breast epithelial cells. Oncogene.
21:8001–8010. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dagher SF, Wang JL and Patterson RJ:
Identification of galectin-3 as a factor in pre-mRNA splicing. Proc
Natl Acad Sci USA. 92:1213–1217. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Newlaczyl AU and Yu LG: Galectin-3 - a
jack-of-all-trades in cancer. Cancer Lett. 313:123–128. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Boer RA, van Veldhuisen DJ, Gansevoort
RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJL and van
der Harst P: The fibrosis marker galectin-3 and outcome in the
general population. J Intern Med. 272:55–64. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Acosta-Rodríguez EV, Montes CL, Motrán CC,
Zuniga EI, Liu FT, Rabinovich GA and Gruppi A: Galectin-3 mediates
IL-4-induced survival and differentiation of B cells: Functional
cross-talk and implications during Trypanosoma cruzi infection. J
Immunol. 172:493–502. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bernardes ES, Silva NM, Ruas LP, Mineo JR,
Loyola AM, Hsu DK, Liu FT, Chammas R and Roque-Barreira MC:
Toxoplasma gondii infection reveals a novel regulatory role for
galectin-3 in the interface of innate and adaptive immunity. Am J
Pathol. 168:1910–1920. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferraz LC, Bernardes ES, Oliveira AF, Ruas
LP, Fermino ML, Soares SG, Loyola AM, Oliver C, Jamur MC, Hsu DK,
et al: Lack of galectin-3 alters the balance of innate immune
cytokines and confers resistance to Rhodococcus equi infection. Eur
J Immunol. 38:2762–2775. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ruas LP, Bernardes ES, Fermino ML, de
Oliveira LL, Hsu DK, Liu FT, Chammas R and Roque-Barreira MC: Lack
of galectin-3 drives response to Paracoccidioides brasiliensis
toward a Th2-biased immunity. PLoS One. 4:e45192009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fukumori T, Takenaka Y, Yoshii T, Kim HR,
Hogan V, Inohara H, Kagawa S and Raz A: CD29 and CD7 mediate
galectin-3-induced type II T-cell apoptosis. Cancer Res.
63:8302–8311. 2003.PubMed/NCBI
|
|
13
|
Silverman AM, Nakata R, Shimada H, Sposto
R and DeClerck YA: A galectin-3-dependent pathway upregulates
interleukin-6 in the microenvironment of human neuroblastoma.
Cancer Res. 72:2228–2238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Demotte N, Wieërs G, Van Der Smissen P,
Moser M, Schmidt C, Thielemans K, Squifflet JL, Weynand B, Carrasco
J, Lurquin C, et al: A galectin-3 ligand corrects the impaired
function of human CD4 and CD8 tumor-infiltrating lymphocytes and
favors tumor rejection in mice. Cancer Res. 70:7476–7488. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Breuilh L, Vanhoutte F, Fontaine J, van
Stijn CM, Tillie-Leblond I, Capron M, Faveeuw C, Jouault T, van Die
I, Gosset P, et al: Galectin-3 modulates immune and inflammatory
responses during helminthic infection: Impact of galectin-3
deficiency on the functions of dendritic cells. Infect Immun.
75:5148–5157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu SY, Yu JS, Liu FT, Miaw SC and Wu-Hsieh
BA: Galectin-3 negatively regulates dendritic cell production of
IL-23/IL-17-axis cytokines in infection by Histoplasma capsulatum.
J Immunol. 190:3427–3437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen HY, Fermin A, Vardhana S, Weng IC, Lo
KF, Chang EY, Maverakis E, Yang RY, Hsu DK, Dustin ML and Liu FT:
Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation
at the immunological synapse. Proc Natl Acad Sci USA.
106:14496–14501. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang W, Guo H, Geng J, Zheng X, Wei H, Sun
R and Tian Z: Tumor-released Galectin-3, a soluble inhibitory
ligand of human NKp30, plays an important role in tumor escape from
NK cell attack. J Biol Chem. 289:33311–33319. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka
N, Habuchi T, Horikawa Y, Hashimoto Y, Yoneyama T, Mori K, Koie T,
et al: A novel strategy for evasion of NK cell immunity by tumours
expressing core2 O-glycans. EMBO J. 30:3173–3185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Iurisci I, Tinari N, Natoli C, Angelucci
D, Cianchetti E and Iacobelli S: Concentrations of galectin-3 in
the sera of normal controls and cancer patients. Clin Cancer Res.
6:1389–1393. 2000.PubMed/NCBI
|
|
21
|
Iacovazzi PA, Notarnicola M, Caruso MG,
Guerra V, Frisullo S, Altomare DF and Correale M: Serum levels of
galectin-3 and its ligand 90k/mac-2bp in colorectal cancer
patients. Immunopharmacol Immunotoxicol. 32:160–164. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen C, Duckworth CA, Zhao Q, Pritchard
DM, Rhodes JM and Yu LG: Increased circulation of galectin-3 in
cancer induces secretion of metastasis-promoting cytokines from
blood vascular endothelium. Clin Cancer Res. 19:1693–1704. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng D, Liang B and Li Y: Serum
galectin-3 as a potential marker for gastric cancer. Med Sci Monit.
21:755–760. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sakaki M, Oka N, Nakanishi R, Yamaguchi K,
Fukumori T and Kanayama HO: Serum level of galectin-3 in human
bladder cancer. J Med Invest. 55:127–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saussez S, Lorfevre F, Lequeux T, Laurent
G, Chantrain G, Vertongen F, Toubeau G, Decaestecker C and Kiss R:
The determination of the levels of circulating galectin-1 and −3 in
HNSCC patients could be used to monitor tumor progression and/or
responses to therapy. Oral Oncol. 44:86–93. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ulu M, Alacacioglu A, Yuksel E, Pamukk BO,
Bozkaya G, Ari A, Yuksel A, Sop G and Alacacioglu I: Prognostic
significance of serum galectin-3 levels in patients with
hepatocellular cancer and chronic viral hepatitis. Saudi J
Gastroenterol. 21:47–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Išić T, Savin S, Cvejić D, Marečko I,
Tatić S, Havelka M and Paunović I: Serum Cyfra 21.1 and galectin-3
protein levels in relation to immunohistochemical cytokeratin 19
and galectin-3 expression in patients with thyroid tumors. J Cancer
Res Clin Oncol. 136:1805–1812. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xie L, Ni WK, Chen XD, Xiao MB, Chen BY,
He S, Lu CH, Li XY, Jiang F and Ni RZ: The expressions and clinical
significances of tissue and serum galectin-3 in pancreatic
carcinoma. J Cancer Res Clin Oncol. 138:1035–1043. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vereecken P, Zouaoui Boudjeltia K, Debray
C, Awada A, Legssyer I, Sales F, Petein M, Vanhaeverbeek M, Ghanem
G and Heenen M: High serum galectin-3 in advanced melanoma:
Preliminary results. Clin Exp Dermatol. 31:105–109. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bergström K and Lefvert AK: An automated
turbidimetric immunoassay for plasma proteins. Scand J Clin Lab
Invest. 40:637–640. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kleine TO and Merten B: Rapid manual
immunoturbidimetric and immunonephelometric assays of prealbumin,
albumin, IgG, IgA and IgM in cerebrospinal fluid. J Clin Chem Clin
Biochem. 18:245–254. 1980.PubMed/NCBI
|
|
32
|
Hittelet A, Legendre H, Nagy N, Bronckart
Y, Pector JC, Salmon I, Yeaton P, Gabius HJ, Kiss R and Camby I:
Upregulation of galectins-1 and −3 in human colon cancer and their
role in regulating cell migration. Int J Cancer. 103:370–379. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nakamura M, Inufusa H, Adachi T, Aga M,
Kurimoto M, Nakatani Y, Wakano T, Nakajima A, Hida JI, Miyake M, et
al: Involvement of galectin-3 expression in colorectal cancer
progression and metastasis. Int J Oncol. 15:143–148.
1999.PubMed/NCBI
|
|
34
|
Yazawa T, Shibata M, Gonda K, Machida T,
Suzuki S, Kenjo A, Nakamura I, Tsuchiya T, Koyama Y, Sakurai K, et
al: Increased IL-17 production correlates with immunosuppression
involving myeloid-derived suppressor cells and nutritional
impairment in patients with various gastrointestinal cancers. Mol
Clin Oncol. 1:675–679. 2013.PubMed/NCBI
|
|
35
|
Balkwill F and Mantovani A: Cancer and
inflammation: Implications for pharmacology and therapeutics. Clin
Pharmacol Ther. 87:401–406. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Inoue Y, Nezu R, Matsuda H, Takagi Y and
Okada A: Rapid turnover proteins as a prognostic indicator in
cancer patients. Surg Today. 25:498–506. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vanlandingham S, Spiekerman AM and Newmark
SR: Prealbumin: A parameter of visceral protein levels during
albumin infusion. JPEN J Parenter Enteral Nutr. 6:230–231. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Delpeuch F, Cornu A and Chevalier P: The
effect of iron-deficiency anaemia on two indices of nutritional
status, prealbumin and transferrin. Br J Nutr. 43:375–379. 1980.
View Article : Google Scholar : PubMed/NCBI
|
